| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2020 | ZTS Zoetis Inc. | Trawicki Roman48 | Executive Vice President | Sell | 5,499 | $143.42 | $788,666.58 | -56.3% | |
| Feb 19, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 8,000 | $12.51 | $100,080.00 | -27.1% | |
| Feb 19, 2020 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 4,463 | $143.41 | $640,038.83 | -11.1% | |
| Feb 18, 2020 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 20,000 | $63.90 | $1,278,000.00 | -0.7% | |
| Feb 14, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 17,016 | $12.14 | $206,611.68 | -63.3% | |
| Feb 14, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 11,472 | $12.14 | $139,295.32 | -10.4% | |
| Feb 14, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 8,140 | $12.14 | $98,784.60 | -11.8% | |
| Feb 14, 2020 | KNSA Kiniksa Pharmaceuticals International, Plc | Beetham Thomas W. | EVP &Chief Legal Officer | Sell | 59 | $18.58 | $1,096.22 | - | |
| Feb 14, 2020 | KNSA Kiniksa Pharmaceuticals International, Plc | Paolini John F.51 | SVP &Chief Medical Officer | Sell | 11,316 | $18.29 | $207,011.20 | -23.9% | |
| Feb 13, 2020 | TLRY Tilray Brands, Inc. | Kennedy Brendan87 | President And CEO | Sell | 100,000 | $16.28 | $1,627,590.00 | -2.1% | |
| Feb 13, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Sabag Mark | See "remarks" Below | Sell | 72,131 | $13.03 | $939,759.98 | -100% | |
| Feb 12, 2020 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 20,000 | $62.90 | $1,258,000.00 | -0.7% | |
| Feb 10, 2020 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 3,000 | $48.81 | $146,430.00 | -8.0% | |
| Feb 10, 2020 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 4,799 | $12.27 | $58,883.73 | -26.3% | |
| Feb 10, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 3,144 | $12.24 | $38,487.90 | -13.2% | |
| Feb 10, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, Growth Markets Commercial | Sell | 4,155 | $12.24 | $50,864.26 | -18.4% | |
| Feb 10, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 5,544 | $12.27 | $68,024.88 | -14.3% | |
| Feb 10, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 5,669 | $12.27 | $69,558.63 | -23.9% | |
| Feb 10, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 6,199 | $12.24 | $75,886.30 | -41.9% | |
| Feb 10, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 12,538 | $12.24 | $153,471.39 | -80.8% | |
| Feb 10, 2020 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 29,984 | $104.52 | $3,133,912.11 | -30.1% | |
| Feb 7, 2020 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 1,623 | $103.31 | $167,675.38 | -17.9% | |
| Feb 7, 2020 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,522 | $103.32 | $157,247.10 | -5.9% | |
| Feb 7, 2020 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 3,248 | $103.35 | $335,696.07 | -0.7% | |
| Feb 7, 2020 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 2,030 | $103.32 | $209,747.31 | -9.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.